Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Tsuneyoshi IIDA

Retrospective Diagnosis of Feline GM2 Gangliosidosis Variant 0 (Sandhoff-Like Disease) in Japan: Possible Spread of the Mutant Allele in the Japanese Domestic Cat Population

Journal of Veterinary Medical Science

Veterinary

2008

English

Related publications

Biochemical Characterization of the GM2 Gangliosidosis B1 Variant

Brazilian Journal of Medical and Biological Research

English

Deficiency of the Hexosaminidase a Activator Protein in a Case of GM2 Gangliosidosis; Variant AB

English

GM2-Gangliosidosis, AB Variant: Clinical, Ophthalmological, MRI, and Molecular Findings

English

711. Intravenous Neonatal Gene Therapy Corrects GM2 Gangliosidosis in Sandhoff Mice for Long-Term, by Using AAV Viral Vector Expressing a New Hexosaminidase Variant

English

377. Significant Therapeutic Benefit After Post-Symptomatic Gene Therapy in a Feline Model of GM2 Gangliosidosis

English

Partial Deficiency of Beta-Hexosaminidase Activity in Canine GM2-gangliosidosis.

Tohoku Journal of Experimental Medicine

English

Biomarkers for Disease Progression and AAV Therapeutic Efficacy in Feline Sandhoff Disease

Experimental Neurology

Developmental Neuroscience

Neurology

2015

English

Therapeutic Response in Feline Sandhoff Disease Despite Immunity to Intracranial Gene Therapy

English

Molecular Consequences of the Pathogenic Mutation in Feline GM1 Gangliosidosis

Molecular Genetics and Metabolism

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Tsuneyoshi IIDA

Retrospective Diagnosis of Feline GM2 Gangliosidosis Variant 0 (Sandhoff-Like Disease) in Japan: Possible Spread of the Mutant Allele in the Japanese Domestic Cat Population

Related publications

Biochemical Characterization of the GM2 Gangliosidosis B1 Variant

Deficiency of the Hexosaminidase a Activator Protein in a Case of GM2 Gangliosidosis; Variant AB

GM2-Gangliosidosis, AB Variant: Clinical, Ophthalmological, MRI, and Molecular Findings

711. Intravenous Neonatal Gene Therapy Corrects GM2 Gangliosidosis in Sandhoff Mice for Long-Term, by Using AAV Viral Vector Expressing a New Hexosaminidase Variant

377. Significant Therapeutic Benefit After Post-Symptomatic Gene Therapy in a Feline Model of GM2 Gangliosidosis

Partial Deficiency of Beta-Hexosaminidase Activity in Canine GM2-gangliosidosis.

Biomarkers for Disease Progression and AAV Therapeutic Efficacy in Feline Sandhoff Disease

Therapeutic Response in Feline Sandhoff Disease Despite Immunity to Intracranial Gene Therapy

Molecular Consequences of the Pathogenic Mutation in Feline GM1 Gangliosidosis